Synaptic dysfunction in congenital myasthenic syndromes

Annals of the New York Academy of Sciences

Volumn 1275, Issue 1, 2012, Pages 63-69

  Beeson, David ^a  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

Congenital myasthenic syndrome; DOK7; Functional diagnostics; Low conductance mutation, DPAGT1

Indexed keywords

ADAPTOR PROTEIN; CHOLINERGIC RECEPTOR; DOK7 PROTEIN; EPHEDRINE; FLUOXETINE; NEUROTRANSMITTER; SALBUTAMOL; UNCLASSIFIED DRUG;

ARTICLE; CONGENITAL MYASTHENIC SYNDROME; DNA SEQUENCE; GENE DISRUPTION; GENE MUTATION; GENETIC DISORDER; GENETIC SCREENING; GENETIC VARIABILITY; MUTATIONAL ANALYSIS; NEUROMUSCULAR TRANSMISSION; NEUROTRANSMITTER RELEASE; TREATMENT DURATION;

EID: 84871543511     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/nyas.12000     Document Type: Article

References (29)

1. Engel, A.G. 2012. Current status of the congenital myasthenic syndromes. Neuromuscul. Disord. 22: 99-111.
2. Chaouch, A., D. Beeson, D. Hantaï & H. Lochmüller 2012. 186th ENMC international workshop: congenital myasthenic syndromes 24-26 June 2011, Naarden, The Netherlands. Neuromuscul. Disord. 22: 566-576.
3. Engel, A.G. 2007. The therapy of congenital myasthenic syndromes. Neurotherapeutics 4: 252-257.
4. Abicht, A. et al. 1999. A common mutation (epsilon1267delG) in congenital myasthenic patients of Gypsy ethnic origin. Neurology 53: 1564-1569.
5. Richard, P. et al. 2008. The CHRNE 1293insG founder mutation is a frequent cause of congenital myasthenia in North Africa. Neurology 71: 1967-1972.
6. Müller, J.S. et al. 2004. The congenital myasthenic syndrome mutation RAPSN N88K derives from an ancient Indo-European founder. J. Med. Genet. 41: e104.
7. Okada, K. et al. 2006. The muscle protein Dok-7 is essential for neuromuscular synaptogenesis. Science 312: 1802-1805.
8. Sherry, S.T. et al. 2001. dbSNP: the NCBI database of genetic variation. Nucleic Acids Res. 29: 308-311.
9. Sanes, J.R. & J.W. Lichtman. 2001. Induction, assembly, maturation and maintenance of a postsynaptic apparatus. Nat. Rev. Neurosci. 2: 791-805.
10. Zhang, B. et al. 2008. LRP4serves as a coreceptor of agrin. Neuron 60: 285-297.
11. Kim, N. et al. 2008. Lrp4 is a receptor for Agrin and forms a complex with MuSK. Cell 135: 334-342.
12. Beeson, D. et al. 2006. Dok-7 mutations underlie a neuromuscular junction synaptopathy. Science 313: 1975-1978.
13. Cossins, J. et al. 2012. The spectrum of mutations that underlie the neuromuscular junction synaptopathy in DOK7 congenital myasthenic syndrome. Hum. Mol. Genet. 21: 3765-3775.
14. Müller, J.S. et al. 2007. Phenotypical spectrum of DOK7 mutations in congenital myasthenic syndromes. Brain 130: 1497-1506.
15. Palace et al. 2007. Clinical features of the DOK7 neuromuscular junction synaptopathy. Brain 130: 1507-1515.
16. Selcen, D. et al. 2008. Dok-7 myasthenia: phenotypic and molecular genetic studies in 16 patients. Ann. Neurol. 64: 71-87.
17. Maselli, R.A. et al. 2012. LG2 agrin mutation causing severe congenital myasthenic syndrome mimics functional characteristics of non-neural (z-) agrin. Hum. Genet. 131: 1123-1135.
18. Ammar, A.B. et al. 2010. Phenotype genotype analysis in 15 patients presenting a congenital myasthenic syndrome due to mutations in DOK7. J. Neurol. 257: 754-766.
19. Ohno, K. et al. 1995. Congenital myasthenic syndrome caused by prolonged acetylcholine receptor channel openings due to a mutation in the M2 domain of the epsilon subunit. Proc. Natl. Acad. Sci. USA 92: 758-762.
20. Webster, R. et al. 2012. A novel congenital myasthenic syndrome due to decreased acetylcholine receptor ion-channel conductance. Brain 135: 1070-1080.
21. Palace, J. et al. 2012. Clinical features in a series of fast channel congenital myasthenia syndrome. Neuromuscul. Disord. 22: 112-117.
22. Senderek, J. et al. 2011. Hexosamine biosynthetic pathway mutations cause neuromuscular transmission defect. Am. J. Hum. Genet. 88: 162-172.
23. Belaya, K. et al. 2012. Mutations in DPAGT1 cause a limb-girdle congenital myasthenic syndrome with tubular aggregates. Am. J. Hum. Genet. 91, 193-201.
24. Lashley, D., J. Palace, S. Jayawant, et al. 2010. Ephedrine treatment in congenital myasthenic syndrome due to mutations in DOK7. Neurology 74: 1517-1523.
25. Schara, U. et al. 2009. Ephedrine therapy in eight patients with congenital myasthenic syndrome due to DOK7 mutations. Neuromuscul. Disord. 19: 828-832.
26. Liewluck, T., D. Selcen & A.G. Engel 2011. Beneficial effects of albuterol in congenital endplate acetylcholinesterase deficiency and Dok-7 myasthenia. Muscle Nerve 44: 789-794.
27. Burke, G. et al. 2011. Salbutamol treatment in children with DOK7 congenital myasthenic syndrome. Eur. J. Paed. Neurol. 15(Suppl 1): 2 Abstract.
28. Chan, S.H., V.C. Wong & A.G. Engel. 2012. Neuromuscular junction acetylcholinesterase deficiency responsive to albuterol. Pediatr. Neurol. 47: 137-140.
29. Sadeh, M., X.M. Shen & A.G. Engel. 2011. Beneficial effect of albuterol in congenital myasthenic syndrome with epsilon-subunit mutations. Muscle Nerve 44: 289-291.